Of note, reduction of AHR determined a significant decrease in CLL cell viability (from 53.0% ± 4.1% to 42.3% ± 4.8%, p = 0.003) (Figure 4C). This evidence concerns the gene AHR and B-cell chronic lymphocytic leukemia.